The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...

The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...

Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...

The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...

EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer ...

ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US and EU, ONCOLife is ...

The Phase III SUNMO trial could mark a breakthrough for transplant-ineligible patients with relapsed or refractory large B-cell lymphoma. In this ONCOLife interview, we spoke with Dr. Jason Westin, ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s anti–PD-1 therapy pembrolizumab (KEYTRUDA®), potentially expanding ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...

AstraZeneca has reached a wide-ranging agreement with the Trump administration to cut prescription drug prices for American patients—offering up to 80% discounts via TrumpRx.gov—while investing $50 ...

Roche has announced that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Elecsys pTau217 blood test for the diagnosis of Alzheimer’s disease. This ...